INTRODUCTION
Vaccine efficacy and effectiveness (VE) are generally estimated as one minus some measure of relative risk (RR) in the vaccinated group compared with the unvaccinated group: VE -1 -RR.
(
Due to the dependent happenings in infectious diseases (1), vaccination can produce several different kinds of effects, at both the individual and the population levels. The groups being compared could be composed of individuals or of populations or communities. Vaccination can induce a biologically protective response in a vaccinated individual or reduce the degree or duration of infectiousness for other individuals. Widespread vaccination in a population can reduce transmission and produce indirect effects, even in individuals who were not vaccinated. Vaccinated people might change their rate of making contacts with potentially infectious sources and alter the overall benefits of vaccination. In designing a study to evaluate the effects of vaccination, the question of interest guides the choice of unit of observation, comparison groups, parameter of effect, and level of information required (2) . In this presentation we review different measures of effect of vaccination and vaccination programs. We consider various study designs for estimating the different measures of effect based on the choice of corn-parison groups, the unit of observation, the choice of parameter, and the amount of information about the transmission system required for estimation. Our focus is on field studies that may be double-blinded, placebo controlled phase III trials, or phase IV post-licensure studies that may be randomized or observational. We regard the paradigm of the randomized, double-blinded study as the point of departure for interpreting observational and nonrandomized studies (3, 4) . Case-control studies produce approximate estimators of the appropriate population parameters (5, 6) . Our primary concerns here are concepts of design and interpretation of the estimates. For example, what does it mean exactly when we say that a vaccine is 85 percent efficacious?
We begin by discussing some biologic aspects of vaccination that are of interest or that need to be taken into account when estimating vaccine efficacy. Following that, we discuss designs for estimating the direct protective effect of vaccination. Next we present design options for evaluating how vaccination alters the infectiousness of a person who becomes infected. We then consider that a vaccination may result in change in behavior, altering the exposure to infection. Continuing on, we present community-based study designs for estimating the indirect, total, and overall effectiveness of widespread vaccination in populations. We conclude by touching upon the problem of evaluating safety and adverse events. Table 1 (2) provides an overview of several different types of effects and the parameters used to estimate them. Historically, the primary effect of interest of vaccination has been how well it protects the vaccinated individual. Biologically, the protective immune response can reduce the probability that a person becomes infected given a specified exposure to or inoculum of an infectious agent. That is, it can reduce the transmission probability. If a vaccinated person becomes infected, the immune response might reduce the degree or duration of disease or the probability of dying from the disease. It may also alter the rate of disease progression. For many infectious agents with 74 Halloran et al. figure 3) . The subscripts S, /, and T denote susceptibility, infectiousness, and combined effects, respectively. The Cox proportional hazards estimator is denoted by e pi . Time has been omitted from the table for notational clarity. t VE, vaccine efficacy/effectiveness; NA, not applicable.
EFFECTS OF INTEREST
short incubation periods, disease is used as the outcome of interest in vaccine trials rather than infection. Becoming infected results with some probability from contact with an infectious source, while developing disease depends on the within host interaction subsequent to successful infection. In many vaccine studies, the distinction between infection and disease as outcome is not made. Studies with either of these outcomes are sometimes used to measure vaccine efficacy for susceptibility (VE S ) (third column, table 1), though the distinction between infection and disease should always be kept in mind.
Another measure of effect evaluates the degree of protection once a person has become infected. We call this vaccine efficacy for progression (VE P ) (not in table 1). With infectious agents that have long incubation periods, such as tuberculosis or human immunodeficiency virus (HIV), evaluation of this sort of effect is particularly important. Another example of VE/. is the comparison of the degree of illness conditional on becoming sick. For example, vaccinated persons who contract chickenpox generally have much milder disease than unvaccinated persons who contract the same disease.
The main distinction between VE 5 and VE P is that studies to estimate VE 5 evaluate susceptibles and the exposure to infection would need to be taken into account. Studies to estimate VE P are conditional on the participants already being infected, so the progression within infected individuals is important. Studies to evaluate VE S that use disease as an outcome often do not differentiate the protective effects against infection and against disease conditional upon infection. Nonlinearities of the pathway from infection to manifest disease could mean that the efficacy as measured by the observed outcome would be quite different from the biologic efficacy if it could be measured along the pathway (7) . The difference should be kept in mind when designing, analyzing, and interpreting the study.
A vaccinated person who becomes infected may also be less infectious to other susceptibles or be infectious for a shorter period of time. The vaccine efficacy for infectiousness (VE ; ) (table 1, top row, columns 4 and  5) , is of interest because a vaccine that reduces infectiousness could have important public health consequences. Vaccination could also change the distribution of carriers in a population.
Widespread vaccination can have indirect effects for unvaccinated people as well as for vaccinated people. The indirect effects are due to the change in collective level of immunity in the population due to vaccination. The collective level of immunity in a population against a particular parasite is called herd immunity. It is important to differentiate between the indirect effects in the unvaccinated and vaccinated groups. These are called the indirect and total effectiveness, respectively (table 1, middle, columns 4 and 5). The indirect effects in unvaccinated people might not be the same as those in the vaccinated people. The overall effectiveness of a vaccination strategy or allocation within a particular population is the weighted average of the outcomes in the vaccinated and the unvaccinated people (table 1, middle, column 6).
To evaluate the direct protective effects of vaccination, VE S and VE P , usually the individual is the unit of observation. To evaluate VE /5 generally small transmission units, such as households or partnerships in which contacts can be defined, are needed. This type of study in small transmission units can also be used to evaluate VE S (table 1, top row). To evaluate the population level effects, the unit of observation becomes the population, so that several populations need to be included in the study (table 1, bottom right portion; see below in the discussion of figure 3 ).
Vaccination can induce heterogeneous response, and protection might wane or be boosted by exposure to wild-type infection. Exposure to infection might be heterogeneous within comparison groups. Vaccine antigen mixes might be effective against some strains, but not others. Belief in the protective effects of vaccination could result in people increasing their exposure to infection. These characteristics affect the interpretation of the vaccine efficacy estimates. In the following sections, we review some of the issues related to evaluating each of the various effects.
VACCINE EFFECT ON SUSCEPTIBILITY, VE S
We first consider study designs for estimating the protective effects of vaccination, VE S . In table 1, these are represented in the third column. Important for choosing methods to estimate VE S and for interpreting VE S estimates is to consider some model for the protection conferred by the vaccine (8) . To begin, suppose that vaccination provides a multiplicative reduction in the probability of being infected given a specified exposure to infection or a specified inoculum. That is, the transmission probability in a vaccinated person is a fraction, denoted by 0, of that in an unvaccinated person. We then define VE 5 = 1 -9 , where VE S represents the proportionate reduction in the transmission probability given a specified exposure to infection.
Under the assumption of equal exposure to the infectious agent in the vaccinated and unvaccinated groups (9), the estimates of VE S are obtained from the relative risk of infection or disease in the vaccinated individuals compared with the unvaccinated individuals:
where R denotes one of the measures of risk. Given our assumption about the multiplicative effect of the vaccine on the transmission probability, if we can estimate the relative transmission probability to the vaccinated compared with the unvaccinated individuals, then we can estimate VE S = 1 -9 . However, this requires information on exposure to infection, which is often difficult or impossible to obtain. The incidence rate, hazard rate, and cumulative incidence (or incidence proportion) are measures of disease frequency that generally do not require knowledge of contacts with infectives to estimate. They also can be used to estimate VE 5 , but then the interpretation of the estimated efficacy is different.
VE S based on the transmission probability
Let the transmission probability, denoted /?,-,, be the probability that, conditional upon a contact between an infective source with covariate status / and a susceptible host with covariate status j , successful transfer and establishment of the infectious agent will occur. The transmission probability could also be defined conditional on a specified level of inoculum. A related concept is the secondary attack rate, (SAR,-,), defined as the proportion of susceptibles with covariate status j making contact with an infectious person of covariate status i who become infected.
Let 0 and 1 denote being unvaccinated and vaccinated, respectively. Then, for example, p 0l denotes the transmission probability per contact from an unvaccinated infective person to a vaccinated uninfected person. Let p 0 andpj, denote the transmission probability to unvaccinated and vaccinated susceptibles, respectively, where the dot in the subscript can denote any vaccine status or an average across the population.
Then VE Sp based on the transmission probability or secondary attack rate ( Estimating vaccine efficacy from the transmission probability ratios requires information on who is infectious and when, and whom they contact and how. The concept of a contact is very broad and must be defined in each particular study. Often it is defined within a small transmission unit such as a household or sexual partnership. For a sexually transmitted disease, the contact could be defined per sex act or per partnership. For pertussis, a contact could be defined as attending school the same day as an infectious person or as living in the same household during the entire period of infectiousness of a case. The mode of transmission of a parasite determines what types of contacts are potentially infectious.
The type of contact and the infectiousness of the infective source will determine the inoculum level per contact. A vaccine that is protective against a low inoculum might not protect against a high inoculum. If it were possible to measure the infectiousness of the infectives, the covariate^ in the transmission probability might include information about this, and, therefore, provide a means to stratify by inoculum level in computing the efficacy estimates. Similarly, if it were possible to measure the different types of contacts, then the transmission probability for each type of contact could be estimated, and the VE 5p estimates could be stratified by type of contact. If it is not possible to measure the levels of infectiousness, the inoculum level, or the different types of contacts, then the estimates will reflect the unmeasured heterogeneities.
There are two main ways to design a study to estimate the relative transmission probabilities. The first method, called the secondary attack rate (10-13), or case-contact rate method, has been used since the pertussis vaccine trials in 1930s (14) to estimate vaccine efficacy. In this case, the focus is on identifying the infected individuals and the proportion of people exposed to them who become infected. Another method of estimating the transmission probability is based on the binomial model. In this case, we observe susceptible people, count the number of contacts they make with infectives, and count the number of these susceptible people who become infected. The transmission probability is estimated using the binomial model. Secondary attack rate studies are commonly used for directly transmitted infectious agents with high transmission probabilities, such as measles, chickenpox, mumps, pertussis, and tuberculosis. Contacts are often defined within small transmission units such as households. In tuberculosis, contact tracing and testing are often used to estimate the secondary attack rates. The binomial model is commonly used in studies with low transmission probabilities, such as HIV, in which susceptibles often make more than one contact before becoming infected. The ascertainment of the susceptibles or infectives can occur prospectively or retrospectively, depending on the design of the study.
VE S not conditional on knowledge of exposure to infection
Information on exposure to infection is often difficult or impossible to collect. More commonly, studies are designed to estimate VE 5 from events per persontime of potential rather than actual exposure or simply from the proportion of people who become infected in the vaccinated compared with the unvaccinated groups. Standard parameters for estimating VE S are incidence rates, hazard rates, or cumulative incidence. Halloran and Struchiner (5, 15) called these comparisons study design type I (table 1, third column, lower rows). Here information on actual exposure to infection is not required to estimate VE S . The assumption is made that the vaccinated and unvaccinated groups are equally exposed to infection (9) , so that any differences in the risk in the two groups is due to the biologic effects of the vaccine.
Estimation of the different VE S parameters requires differing levels of information and make different demands on study design and data collection (16) . Incidence rates or hazard rates require the time to event and the period of potential exposure of each person under study. The hazard rate in infectious diseases is often called the force of infection. A Cox proportional hazards model requires only the ordering of the event times. An estimate of cumulative incidence requires only final value data, that is, whether an infection occurred by the end of the study or not. Correspondingly, in table 1, VE 5IR based on incidence rates (IR) and VE SJl are level II parameters, VE 5PH based on Cox proportional hazards (PH) is level III, and VE 5 CI based on cumulative incidence (CI) or final value data is level IV. Each level requires less information about the transmission system, with only level I requiring actual contact information. Thus, the levels form a hierarchy. Since VE S p based on the transmission probability is defined conditional on exposure to infection, it is called a conditional parameter, while the other measures are called unconditional parameters.
Primary vaccine efficacy studies often report VE S I R based on relative events per person time, or level El information,
The usual assumption is that the numbers of events follow a Poisson distribution. Similarly, investigators may estimate the hazard rates in the vaccinated and unvaccinated X x (t) and ^( 0 , respectively, using survival analysis methods. Then the VE S is based on the hazard rate ratio VE 5 x (t) = 1 -. When covariates such as age and gender are added, the analyses are stratified by the covariates or Poisson regression can be used. Under the assumption that the effect of the vaccine is multiplicative, constant, and homogeneous, the Cox proportional hazards model can be used. In this case, it is not necessary to estimate the hazard rate in the unvaccinated group, but only the relative hazard rate. This requires only the ordering of the infection times, as mentioned above. Covariates including timedependent covariates can easily be incorporated using standard software. An early example of estimating VE 5IR is the study by Kendrick and Eldering of pertussis vaccine in the 1930s (14) , which reported both the proportion of people exposed to infection who developed pertussis, as well the number of cases per person-time. The vaccinated and control groups had 1,815 and 2,397 children, respectively, who contributed 2,268 and 2,307 personyears at risk, respectively. There were 52 cases in the vaccinated and 348 cases in the control group, so 
More recently, Urdaneta et al. (17) present estimates of VE SIR as the result of a randomized, placebo controlled field trial of SPf66 malaria vaccine in Costa Marques, Rondonia, Brazil. A total of 572 participants completed the three dose vaccine schedule and were followed up for 18 months. The 287 vaccinated individuals contributed a total of 12,178 person-weeks at risk, and 76 first Plasmodium falciparum malaria episodes were observed among them. In the placebo group, 285 individuals contributed 11,698 personweeks at risk and 85 cases leading to an estimate of VE 5>IR = 0.14.
In some studies, it is possible to compute both a conditional and an unconditional estimate of vaccine efficacy from a single study. The Kendrick and Eldering study on pertussis vaccine mentioned above also had information on children who had been exposed to pertussis within their own households. In the vaccinated group, 29 of 83 exposed children developed pertussis, while 143 of 160 exposed children in the unvaccinated group developed pertussis. Thus, the estimate of VE Xp is 29 cases/83 vac exposed s ' p 143 cases/160 unvac exposed While everyone is included in the estimate of VE 5IR , only the children with (presumed) exposure to infection are included in the VE 5p estimate. The interpretations of the two estimates are also different, since one measures the protection conferred as measured by infections per person time and the other by the probability of an infection per potentially infectious contact.
Estimation of VE 5CI (r) based on the cumulative incidence requires only information about whether persons are infected or not by the end of the study at time T, that is, final value data:
VE s , a (T) =
vaccinated infection events/persons-at-risk 1 -unvaccinated infection events/persons-at-risk 1 
CI,(7Q
As an example, Greenwood and Yule (9) used the cumulative incidence in studying the efficacy of typhoid vaccination in the troops in the early part of the twentieth century. In one analysis, Greenwood and Yule assumed that the denominators were based on the vaccinated and unvaccinated groups at the beginning of the study. They had 56 cases of typhoid in 10,378 vaccinated soldiers, and 272 cases in 8,936 unvaccinated soldiers. The estimated efficacy based on these numbers is -56 cases/10,378 at-risk VE S C I (7) = 1 0.82 .(4) 5>CIV ' 272 cases/8,936 at-risk A more recent example is the estimation of VE 5CI (7) from a double-blinded live attenuated, cold-adapted influenza vaccine trial in children (18) . In this trial, of the 1,070 children who received vaccine, 14 were infected, and of the 532 children who received placebo, 95 were infected. Infection was defined as being culture positive for influenza virus during the acute phase of an influenza-like illness. Based on these -14/1,070 numbers, VE 5 , CI (r) = 1 -^ = 0.93. Because of the dependent happening structure of events in infectious diseases, there is an intrinsic relation among the different parameters on which the VE 5 estimators are based. Understanding this relation helps to see the relation of the different estimators of VE 5 to one another. Let py be the transmission probability as defined above. Let c denote the contact rate in a population assuming that people are randomly mixing, and let P(i) denote the prevalence of infectives at time t. Then the hazard rate X(t) (or incidence rate or force of infection) at time t can be expressed as the product of the contact rate, the transmission probability, and the probability that a contact is infectious:
So even if the different components of the hazard rate are not measured, we can consider the underlying process that is producing the infections we observe. Similarly, the cumulative incidence, 0 ( 7 } , at some time T is a function of the hazard rate during the follow-up period, and thus also a function of the transmission probability, contact rate, and prevalence of infection in the contacts. Even though the cumulative incidence estimate is a sort of black-box estimator, it is useful in vaccine studies to think about the underlying transmission system that would produce the observed final values.
axis into piece-wise constant components. Then a separate constant VE slR (t) is estimated for each time interval. If there is time dependence, then the estimates will vary across the time intervals. This method of analysis was used to estimate VE 5IR (f) of killed whole-cellonly (WC) and B subunit killed whole-cell (BS-WC) oral cholera vaccines over 3 years (1985) (1986) (1987) (1988) ) of a randomized, double-blinded vaccine trial in rural Matlab, Bangladesh (19) . The placebo was a killed Escherichia coli strain. Participants included 89,596 subjects aged 2-15 years (male and female) and greater than 15 years (females only). The first 3 years of the vaccine trial were partitioned into 1-year segments. Cholera incidence was defined as the number of culture-confirmed cholera episodes per 10 6 persondays of follow-up during each of 3 years.
In the first year of the trial, the estimated incidence rate for those vaccinated with the BS-WC vaccine was 41/10 6 person-days and for the placebo HO/10 6 person-days. 41 Thus, in the first year VE WR (1) = 1 --= 0.63 (one tailed 95 percent confidence limit 0.50). The VE estimates for the BS-WC vaccine for the second and third year of the trial were 0.57 (one tailed 95 percent confidence limit 0.42) and 0.17 (one tailed 95 percent confidence limit -0.15), respectively. Thus, we see a waning time trend in efficacy, with no significant protection by the third year. Since the partitioning boundaries are selected at 1-year intervals, it is not clear if the waning protection is continuous or precisely at what point in time significant protection is lost. With use of a Poisson regression including covariates, the problem still remains of how to partition the time axis into piece-wise constant components. The problem can be solved by the use of survival analysis methods described in the next section.
When estimates of VE S vary with time
In introducing the various VE $ estimators, we made the very simple assumptions that the protective effect was the same multiplicative effect in everyone, that protection did not wane nor was it boosted, and that exposure to infection was not only the same in the vaccinated and unvaccinated groups, but that everyone was exposed equally. Unmeasured heterogeneities in susceptibility, protection, and exposure to infection can produce time-varying estimates of VE SIR (r) or VE 5Jt (f) that are artifacts of the choice of analysis, while true waning of protection or boosting can lead to real time-varying effects.
Consider first the situation that protective efficacy actually wanes with time. One way to build time dependence into the analysis is to partition the time
Nonparametric estimation of time-varying vaccine effects
In this section, we assume that individual or grouped time-to-event data (level II) are available. Durham et al. (20) adapted and compared two basic approaches for the nonparametric estimation of smoothed curves for VE sx (t) = 1 -RR(0 = 1 -r~. The first is a generalized additive models approach that involves using a time-varying coefficient (21) version of the proportional hazards model assuming a Poisson model (22) . It is useful for diagnostics to ascertain the shape of (3(0, but it cannot provide an estimator for VE s x(t). The other method uses Schoenfeld residuals (23, 24) . The general idea is to fit an ordinary proportional hazards model to the data, then to compute the scaled dif-ferences between the actual and expected covariate values at each event time, called Schoenfeld residuals. The scaled residuals are added to the coefficient from the proportional hazards model. The time-varying regression coefficient (3(0 is recovered by smoothing the rescaled Schoenfeld residuals. Conceptually, we are nonparametrically estimating the instantaneous hazard rate ratio e^'\ thus VE sx (t). Both methods provide a hypothesis test for the null H o : P(/) = |3 for all t, that is, for no time-varying effects. The method using the Schoenfeld residuals is easy to use, provides an estimate of e^( I) on the natural scale, and allows easy incorporation of time-dependent covariates, so we recommend this approach in general.
Durham et al. (25) used the method involving Schoenfeld residuals to estimate smooth plots of the VE 5^( 0 for the two oral cholera vaccines from the cholera vaccine trial described above. Figure 1 shows the plot of the VE 5^( 0 estimates and the 95 percent confidence intervals for the two vaccines. The bending downward of the curves is indicative of waning. The p values for the hypothesis test for departures from the proportional hazards assumption are 0.008 and 0.002 for the estimated model of the WC and BS-WC vaccines, respectively. The WC vaccine gives fairly constant and significant protection, with a VE 55t (O of about 0.50 for the first 2.5 years of the trial, but then protection appears to wane rapidly. After 3 years of the trial (May 1988), the point estimate of the VE 5X (0 is 0.245 and the 95 percent confidence interval covers zero. Protection from WC-BS vaccine starts out higher than that from WC vaccine, i.e., 0.713 versus 0.430, but then gradually wanes at a fairly constant rate, i.e., about 2-3 percent per month. This analysis provides a more complete description of the VE S than that based on yearly incidence ratios described above.
Unmeasured heterogeneity (frailty mixture models)
Consider now heterogeneous protection. Smith et al. (8) considered two models for vaccine protection, one which acted homogeneously and multiplicatively on the hazard and the other which protected some people completely against infection while not having any effect on the others. They showed that whether an estimator varies with time depends on the distribution of protection. We extended the discussion of mechanism of protection to the action being directly at the level of the transmission probability (26, 27) . We then developed more general distributions of protection (28) (29) (30) (31) that can include some people who are completely protected, some who have no protection, and the rest having a continuous distribution of protection. Vaccines with a multiplicative effect are called "leaky" (32) , while those conferring complete protection or none at all are called "all-or-none."
With an all-or-none vaccine, the estimator VE X.CI does not vary with time, and provides an estimate of the proportion of the vaccinated completely protected (8) . If VE SIR or VE S x is use( * t o estimate protection of a vaccine conferring all-or-none protection, the estimates will increase with time. This is due to the people with no protection becoming infected, so the uninfected vaccinated group remaining becomes enriched with highly protected people. Thus, the VE S^ appears to increase with time. If a proportion of the vaccinated group is completely protected, and another portion is only partially protected, then there are additional vaccine efficacy parameters of interest to estimate. These include a, the proportion of people completely protected, and 6, the mean reduction in susceptibility in those individuals still at least partially susceptible. The summary measure under heterogeneity is VE 5SUM = 1 -(1 -a)9.
Longini and Halloran (30) derived a frailty mixture model for estimating a, 0, and VE SSUM when there is unmeasured heterogeneity in the vaccine effects on the host's immune response. The model is also applicable if there is heterogeneity in exposure to infection, though the interpretation of the estimates is different. The model falls into the general category of frailty models (33) employed in survival analysis, but like cure models (34), allows for a point mass at zero. It also incorporates the infection process into the baseline hazard rate. The model includes a continuous family of vaccine effect distributions ranging between the two extremes of leaky and all-or-none effects (28) . The model also can be used for individual time-to-event data (35) . Longini and Halloran (30) applied the methods to estimate the VE S of measles vaccine in children from an observational study of a measles outbreak in Muyinga, Burundi. They estimated that a proportion a = 0.80 of the vaccinated children were fully protected (95 percent confidence interval: 0.69,0.92), but the 20 percent without full protection had a higher hazard of measles illness than did the unvaccinated children. This lead to an estimated summary VE 5SUM of only 0.46 (95 percent confidence interval: 0.32, 0.67). The frailty model was shown to provide an adequate fit to the measles data as indicated by a nonsignificant chi-square goodness-of-fit statistic. This validated the use of the frailty model for estimating measles vaccine efficacy in this setting.
Halloran et al. (31) explored the potential use of the above-described frailty mixture model for the estimation of VE 5 over the parameter space that covers the possibilities of most vaccine studies. They showed that the parameters are identifiable under reasonable field conditions as long as there is not too much right censoring. Most importantly, they showed that the conventional VE 5 estimators, i.e., proportional hazards and cumulative incidence, can be considerably biased when unmeasured heterogeneity is present. This bias is removed when the correct frailty mixture model is used.
A general strategy for estimating VE Si
We present a general strategy for estimating VE sx (t) from time-to-event or incidence data. The first step is to conduct diagnostics. Then, with the help of the diagnostics, we find the best estimator of the VE 5 .
Diagnostics. We begin by constructing log-minuslog plots of the Kaplan-Meier or actuarial estimates of the survival curves for the unvaccinated and vaccinated groups, such as those in figure 2a (31) . These plots provide information about whether the vaccine effect is leaky, all-or-none, or a mixture. In addition, they provide some information about whether vaccine induced protection is waning. If the curves are parallel, then the effect is mostly leaky (multiplicative), and we should model the vaccine effect with a proportional hazards model. Any divergence from parallelism indicates time-varying effects and the presence of some form of heterogeneity and/or waning protection. In this case, a model other than the proportional hazards model is needed. If the curves tend to diverge, then there is all-or-none effect, and if they tend to converge, then the model still may be leaky, but with an unmeasured random effect (heterogeneity). Convergence could also indicate waning protection. Although construction of log-minus-log plots is an important first diagnostic step, they are sometimes difficult to interpret (30) . If there are a sufficient number of events, a more informative plot is a smoothed hazard ratio plot of VE sx {t) = 1 ~~ ^i(?)/A^(f) as described above. The possible patterns associated with different vaccine effects are shown in figure 2b (31) . A line with zero slope indicates a purely leaky or multiplicative effect. The researcher can construct a formal hypothesis test for zero slope (20, 24, 25) .
Estimation. If there is no evidence of time-varying effects from the diagnostics, then the VE S PH = 1 -(r can be estimated by fitting a proportional hazards model. If there is evidence of time-varying effects, then the investigator should fit the full family of frailty mixture models. If these models provide an adequate fit to the data, then the estimated parameters may be, but are not necessarily, the appropriate measures of the VE S . If there is evidence of waning or other timevarying effects not attributable to unmeasured heterogeneity, then the nonparametric estimate of VE s (f) itself will provide the best estimate. In this case, it may be possible to construct a time-dependent parametric model of the VE s (r) that would provide tighter confidence intervals than the nonparametric approach.
Interpretation of measures. Which parameter to use to estimate VE S in a particular study depends on the type and duration of the study, the infectious agent and its transmission mode, the resources available, and the assumptions of the distribution of protection within the vaccinated group. Given the above discussion, there are clear limits on the interpretability and generalizability of estimates of VE S . Even if time-dependent effects are detected, knowledge of the underlying biology will need to be used to interpret the effects and to help choose between actual waning, boosting, or heterogeneities. Most vaccine trials nowadays collect data on immune response, some using a data structure of longitudinal data and repeated measures. This information can be used to help estimate and interpret vaccine effects. Also, measuring actual or potential exposure to infection in individuals will help identify heterogeneities in exposure to infection. Some trials of vaccines for vector-borne diseases have entomologic data. These help in quantifying potential exposure to infection.
That randomization does not control for confounding of estimates has been discussed by several authors in the noninfectious disease setting (36-41). Struchiner and Halloran (42) show that these results hold as well in randomized vaccine trials, but a new dimension is added when the possibly omitted covariate is exposure to infection, as is the case when going from VE 5p based on the transmission probability to VE S based on the unconditional estimators. Differences in transmission intensity, previous expo-sure to infection, and preexisting partial immunity and heterogeneities across communities result in different VE S estimates, even when the actual biologic action of the vaccine is the same conditional on these factors. Reporting of any estimate of VE S should include the general elements of the study design, for instance whether the estimate is based on events-per-person time, the transmission probability, or final value data. It should also include indications concerning heterogeneities or time-dependence of efficacy. However, Struchiner et al. (7) demonstrate that the complex biology and possibly nonlinear relation between the biologic mechanism of action of vaccine and the measured outcome make it important to interpret the estimates with caution. Reviews of pertussis vaccine trials in different populations using different estimators consider some of these issues (13, 43) .
In addition, systems of causal inference that define causal effects in terms of potential outcomes (44, 45) , that is the potential outcome if a person receives a certain treatment, say a vaccine, compared with if the person received another treatment, such as a placebo or other vaccine, generally assume that the outcomes in any individual are independent of the treatment assignment of other individuals. It is obvious that this assumption does not hold in most infectious diseases due to the dependent happenings (1). Halloran and Struchiner (46) Additional concerns. The definition of a case in a vaccine study is important. The sensitivity and specificity of the case definition can be crucial in determining the magnitude of the efficacy or effectiveness estimate. Often several case definitions are used in the analysis to explore how changing the case definition alters the estimates of vaccine effect.
It is possible that there are several wild-type strains of a parasite circulating in the host population. The vaccine under investigation may contain just one antigenic variant, or it may contain a cocktail of the several variants, but still not have all the wild-type variants. As molecular epidemiology and immune diagnostic measures improve, strain-specific estimates of VE S and VE, will be in increasing demand. Gilbert et al. (47) discuss statistical methods for inferring how VE S may vary with viral type when several wild-type strains might be circulating in a vaccine study. The methods are presented for final value data, that is level IV, with the further additional information on each infection of what strain of wild-type parasite caused the infection. Additional considerations including adjusting for covariates, multiple events, and complex outcomes, such as malaria in which morbidity is very complex, go beyond the scope of this review.
EFFECT ON PROGRESSION, VE p
As discussed above, the protection conferred by a vaccine if a vaccinated person does become infected is of interest. A vaccine could alter post-infection disease in several possible ways. The outcome of interest could be the probability of developing disease or of death in some specified time interval after becoming infected, the rate of progression to disease after infection, or the severity of illness after becoming infected. Evaluation of the effect of prophylactic vaccination on disease progression, VE/,, requires comparison of morbidity or mortality in vaccinated people who have become infected with that in infected unvaccinated people. Thus, infection status must be determined separately from disease status. If VE P were evaluated by the relative rate of progression to disease, then observation of the infected individuals over time would be required. If VE/. is based on relative morbidity, then appropriate definitions of morbidity levels would be necessary. Similar to the VE S measures discussed above, VE/, would be estimated by one minus the corresponding ratio in the vaccinated compared with the unvaccinated, including in the calculation only those people who had become infected.
VACCINE EFFECT ON INFECTIOUSNESS, VE,
The efficacy of a vaccine in reducing infectiousness, VE 7 , can be estimated epidemiologically by comparing the per-contact transmission probability from vaccinated people who become infected with the transmission probability from unvaccinated people who become infected. The relative risk comparison groups are defined according to the vaccination status of the infectious person contacting the susceptible person (46) . In table 1, the VE, estimate is shown in the second column of the top row of conditional parameters. For completeness, the third column contains the estimate of combined effect of the vaccine in reducing the transmission probability if both the infectious person and the susceptible person in the contact are vaccinated, (VE r ). If we assume that the vaccine has a multiplicative effect in reducing the transmission probability from a vaccinated infectious person to an unvaccinated person, then the efficacy for infectiousness is VE/ = 1 -<{). In contrast to VE 5 , which can be estimated using either conditional or unconditional parameters, the VE/ can generally be estimated using only conditional measures such as the transmission probability or secondary attack rate (46, (48) (49) (50) . By making strong modeling assumptions, Longini et al. (51) suggest a method for estimating the effect of the vaccine on infectiousness using grouped time-to-event data from studies in multiple populations.
Studies for estimating VE, can be incorporated into those for estimating VE 5p based on the transmission probability, if the vaccination status of the infectious person in a contact is known. The analysis can then simply stratify on the vaccination status of both the infectious and susceptible persons in the contact to get estimates of VE 5 , VE,, and VE r . In the case of the binomial model, the likelihood can simply be constructed from the different contributions of each contact, where the parameters 6 for relative susceptibility and § for relative infectiousness are built directly into the likelihood (49, 52) . In this case, it is simplest to assume that the effect on infectiousness and susceptibility are multiplicative and independent, so that/? n , =
Estimating VE S and VE, from multilevel information
In some vaccine studies, there may be information on contacts within transmission units such as households or sexual partnerships, but the individuals may also be exposed to infection outside of the transmission unit. Such an example is the pertussis study by Kendrick and Eldering (14) mentioned above. It may also be that some individuals in a study are not members of clearly defined transmission units. In these cases, it is possible to develop a statistical model to express both the within household transmission probability and the probability of being infected from the community at large (53) . Rather than presenting two separate analyses for conditional and unconditional estimates, the probability model includes the probability of being infected within the transmission unit from contact with an infective and the probability of being infected outside the unit. In essence, then, the model combines elements of level I conditional parameters with elements of levels II, III, or IV unconditional parameters. People who are members of transmission units can contribute information to estimation of both VE 5 and VE,, while people who are not in transmission units and on whom no contact information is available contribute only to estimation of VE 5 .
Augmented vaccine trial design. It is possible to design studies prospectively that intentionally make use of multilevel information in estimating vaccine efficacy. One such design is the augmented trial design (49, 52) . For example, the trial may initially recruit and randomize individuals by some usual eligibility criteria. Then the trial can be augmented by including information on contacts and transmission units such as households or partnerships of the primary trial participants. This is one method to preserve the individual level analysis and randomization that some investigators think is important in randomized controlled trials. The primary analysis can still be focused on estimating VE 5 , although estimation of VE/ is also possible.
Using validation sets in vaccine studies. Collecting information on contacts between infectives and susceptibles, though necessary for estimating VE, and useful for estimating VE 5 , is difficult, expensive, and inherently prone to mismeasurement. An area of current research is the possible use of validation sets for exposure to infection to improve estimation of vaccine efficacy (54) (55) (56) . For example, it might be possible to get good contact information on a small subset of study participants, but only a coarse estimate on everyone else as well as the validation set. Then using methods developed for missing data (57) and two-phase sampling designs (58) (59) (60) (61) (62) , it is possible to decrease bias and increase efficiency by combining the different levels of information.
Efficacy estimates are seriously attenuated when the diagnosis of a particular disease is not cultureconfirmed but based on a nonspecific case definition. For example, if the case definition in an efficacy study of an influenza vaccine is fever and coughing, then the efficacy estimates could be much lower than the efficacy estimates based on culture-confirmed influenza. We are exploring the use of validation sets for outcomes in vaccine efficacy and effectiveness studies. In these designs, the diagnosis of the disease of interest would be confirmed by a specific test in a selected group of the study population. Statistical methods for combining validation sets with the larger main study in which the diagnosis is less specific would be used to obtain efficient, unbiased estimates of vaccine efficacy or effectiveness.
Sample size calculations. Sample size calculations should be based on the analysis method that is going to be used. For example, if the analysis is going to be based on a Cox proportional hazards model with covariates, then the sample size calculation should be based on that model, not on a model using final value data. Sample size calculations are frought with uncertainty. Even if baseline transmission intensities are measured, these may change abruptly during the trial. It is better to be generous in estimating the number of people required in the study. Precise estimation of both VE, and VE/> require larger samples than estimates of VE S because they both are measured on people who have already become infected, which might be a small fraction of the participants. If more complex effects such as waning, frailty models, or VE, are to be estimated, it is good to simulate the proposed vaccine study to examine what numbers of participants are required to produce the precision desired.
CONTACT RATES AND EXPOSURE EFFICACY
Vaccinated people may alter their contact and exposure to infection patterns if they believe the vaccine is protective. Exposure or behavior efficacy is the relative increase or decrease in the relative risk of infection or disease due to the change in exposure to the infectious agent (54) . For example, if we consider the components of the hazard rate as discussed above, changes in exposure to the infectious agent can occur in the rate of contacts, in the prevalence of infection in the contact groups, or in the transmission probability through changing the type of contact. In nonrandomized or observational studies, the vaccinated and unvaccinated groups often differ in their exposure to infection, resulting in biased estimates of VE 5 . Although VE 5 estimates based on the transmission probability require more information than those based on the unconditional parameters, they are less sensitive to bias from unequal exposure to infection in the two groups. The overall effect of biologic protection and change in exposure to infection might be of interest for understanding the public health consequences of vaccination. Study designs need to be explicit about differentiating factors related to susceptibility, such as vaccination status, and factors related to exposure to infection.
INDIRECT, TOTAL, AND OVERALL EFFECTIVENESS
Interest in evaluating the indirect and overall effects of vaccination strategies as part of phase III as well as Table 1 contains examples of the VE nA , VEUB, and VE m based on the usual unconditional measures incidence rate, hazard rate, and cumulative incidence. Many other measures could be used, including average age of infection or the basic reproductive number, RQ.
It is important in choosing the communities or populations to assure that they are separated as much as possible in every way that is relevant for transmission. If the populations are not transmission dynamically separated, then the indirect effects of the programs will not actually differ among the groups, and the study will yield an attenuated estimate of the potential effect of intervention. Transmission patterns can differ greatly among communities. The variability could mask the effects of vaccination. Matching by transmission characteristics is an option to consider (65) .
Exactly what the intervention program of interest is will depend on the vaccine and which subgroups suffer the greatest morbidity. The comparisons may be made between different levels of vaccination coverage, between allocation within different age groups or otherwise defined subgroups. For example, the intervention of interest may be vaccination of school-age children against influenza, with the primary outcome of interest the reduction in influenza incidence in unvaccinated adults. That is, the primary goal of the study might be to evaluate the pure indirect effects in unvaccinated adults. The comparison of interest would be between unvaccinated adults in populations in which children were not vaccinated and unvaccinated adults in populations with vaccinated children. If the risk measure used was cumulative incidence, then the measure would be VE IIACI in unvaccinated adults. Another outcome of interest might be the overall reduction of cumulative incidence in one influenza season in school-age children, VE incI , the indirect effects in unvaccinated children of vaccinating a portion of the children, VE IIA CI , or the total effects in the vaccinated children, VE tIB CI , all compared with unvaccinated children in the unvaccinated populations.
Example
Monto et al. (66) estimated both the protective efficacy, VE S , and the overall effect, VE ni , of an influenza vaccination program. They vaccinated 85 percent of the school-age children in Tecumseh, Michigan, against Hong Kong influenza just before the epidemic in 1968. The 10-week epidemic period was from November 17, 1968 , to January 26, 1969 . The weekly mean influenza illness rates in vaccinated and unvaccinated children were 0.072 and 0.090, respectively. This yields an approximate estimate of 0.072 VE 5 j R ~ 1 = 0.20, which is rather low. The overall influenza illness cumulative incidence in Tecumseh for the epidemic period was 0.14, while the adjusted overall influenza cumulative incidence in unvaccinated, neighboring Adrian, Michigan, was 0.42 for the same period. Using the methods of study design III, the overall effectiveness of vaccinating 85 percent of Tecumseh's school children is estimated to be VE UIjCI~ 1 -0.14/0.42 = 0.67. When designing a population-level study, it is necessary to give some thought to the likely transmission patterns and sources of exposure to infection in a population. These transmission patterns will greatly influence the magnitude of the indirect effects. For instance, if one is interested in evaluating the indirect effects in preschool children of pneumococcal vaccination, one may decide to vaccinate a large fraction of preschool children in several populations and compare it with incidence in preschool children in unvaccinated populations. However, if a large amount of the source of exposure to infection is from older children who are not included in the study, then the indirect effects of vaccination could be quite low. Vaccination of the older children as well may be necessary to have measurable indirect effects.
Because of the great variability among communities, precise definition of the actual intervention of interest will usually be difficult. When designing a study that includes several populations, the definition of the entire allocation and its implementation play an important role in the interpretability of the outcome. There will be limits in the interpretability and general applicability of the results to other settings.
Comparisons across communities would also allow study of other biologic questions. For example, vaccines might contain only particular serotypes or strains of an organism. Widespread vaccination could allow the expansion of nonvaccine serotypes that had been less important before vaccination (67, 68) or put evolutionary pressure on the existing strains. Comparison across populations or before and after introduction of vaccination would be the method to evaluate such changes.
Many issues related to the design and interpretation of studies to evaluate indirect and overall effects are active areas of research and go beyond the scope of this review. Community trials fall into the category of cluster or group randomized trials where whole social units, rather than independent individuals are randomly assigned to treatment groups (65, (69) (70) (71) (72) (73) . The analysis and sample size calculations need to take the clustering and possible group randomization into account. Unmeasured heterogeneity may be dealt with using random effects models in the analysis phase, although such models for use in the dependent happenings setting have not yet been fully developed. Other approaches for examining population level effects include time series and population dynamic models.
Comparison with prevented fractions in noninfectious diseases
The unconditional vaccine effect parameters are analogous to the family of prevented fraction parameters discussed by Greenland and Robins (74, 75) , with some essential differences. In their work, the prevented fraction in the group with a risk factor is estimated by comparing the cumulative incidence in the individuals with a risk factor to cumulative incidence in individuals without the risk factor in a study design similar to study design I with level IV information. The group without the risk factor is supposed to represent what would have happened to the group with the risk factor had it not had the risk factor. The number of prevented cases in the group with the risk factor can be estimated from the prevented fraction based on the cumulative incidence if it is known how many people had the risk factor. Under dependent happenings, however, in study design I, say in population A, the number of cases in the unvaccinated individuals does not represent the number of cases that would have occurred in the unvaccinated individuals had the vaccination program not taken place. If vaccination is widespread enough, the cumulative incidence in the unvaccinated group will usually be lower in the presence of the vaccination program than if no one had been vaccinated. Thus, the estimated number of cases prevented generally will underestimate the actual number of cases prevented in the vaccinated group if calculated using methods for noninfectious diseases as in study design I. The comparison needs to be made between the cumulative incidence in the vaccinated group and what the cumulative incidence would have been in the unvaccinated group if no vaccination program had taken place, as in study design IIB. A similar argument applies to estimation of the prevented hazard fraction.
Multiple questions within a study
Conducting a trial to evaluate effectiveness across several different populations or communities does not preclude evaluating VE S or VE, of vaccination within the populations. A phase lH vaccine trial can be designed to answer several questions at the same time. Randomization within a population can be used to answer efficacy questions, while comparison across populations can be used to evaluate the indirect and overall effects of vaccination. Consider a study of vaccination in several populations to measure the indirect, total, and overall effects of vaccination with different levels of coverage in each population. Within each population, a comparison can be made of the relevant vaccinated and unvaccinated portions of the population to estimate VE IIA , VE IIB and VE m . If information is gathered within the populations on actual contacts, then the effect of the vaccine on infectiousness as well as susceptibility could be evaluated. The most important consideration in designing a vaccine study is to be clear about the effect(s) or question(s) of interest, and the level of information that can be gathered. Then the parameters of interest and the choice of comparison populations should be chosen to provide the effect measures of interest. There is a tradeoff in designing studies to measure both direct and indirect effects of vaccination between vaccinating high numbers of people so that indirect effects are high, and vaccinating too many people so that the number of events in the vaccinated populations is too low to estimate VE 5 or VE, well (51) . Combining estimates of VE 5 and VE, across populations is not necessarily straightforward (42) due to lack of exchangeability (76) .
SAFETY
The Food and Drug Administration in the United States is putting more emphasis on evaluating rare adverse events related to the vaccine during phase III trials. Generally, evaluation of rare adverse events has taken place after licensure when large numbers of people are vaccinated. After licensure, most studies will not be randomized, however, creating challenges for the design and interpretation of such studies. Although this brief section cannot do justice to the problem of safety evaluation, we include it as a reminder that safety evaluation belongs to all phases of vaccine studies.
An example of an adverse event is the possible association between inactivated influenza vaccine and Guillian-Barre syndrome. Since there may be a background level of such events that are not vaccine related, the rate of adverse events in the vaccinated is compared with that in the unvaccinated. If we let these adverse event rates be r x and r 0 in the vaccinated and unvaccinated, respectively, then the null hypothesis that the adverse events are not associated with the vaccine is HQ : /-, < r 0 . We have the inequality in the null hypothesis since we will suspect that the vaccine is associated with the adverse events only if the adverse event rate is greater in the vaccinated. Usually the total number of adverse events is small, thus the event rate is assumed to follow a Poisson distribution. A good strategy for carrying out the above test is to condition on the total number of adverse events in both groups, and then construct the uniformly most powerful unbiased test based on the resulting binomial model (77) . If the number of vaccinated and unvaccinated people at risk is reasonably small, then Fisher's exact test is used. For a large number of vaccinated and unvaccinated people, the binomial approximation is used. Several further approximations for large samples are also available (78) .
In a randomized, double-blinded, phase EH vaccine trial, the unvaccinated group consists of people who get placebo or some other vaccine. However, for unblinded trials, such as large community trials or post-licensure phase IV trials and surveillance, the comparison group must be carefully selected from among unvaccinated comparable people. These types of studies provide an excellent opportunity for adverse events analysis since large numbers of people are vac-cinated, but issues concerning comparability must be addressed (79, 80) .
SUMMARY
There are many different effects to consider when evaluating vaccines in the field. In this review, we have covered some of the various measures and issues related to study design and interpretation of the different measures. We emphasize that in designing and understanding vaccine studies, it is necessary to be specific about what the effect of interest is and about the assumptions underlying the interpretation of the results. Halloran et al. (81) present design, analysis, and interpretation of vaccine studies in more detail.
